Introduction: Optimal treatment of stage I-III breast cancer requires multimodal therapies. Patients can receive these therapies at one or multiple facilities. Herein, we evaluated the association of receiving treatment at more than one facility and distance to that facility on overall survival.
Methods: The 2004-2019 National Cancer Database was queried for patients with stage I-III breast cancer who received at least two modalities of treatment. "Coordinated care" was designated when a patient received all modalities of treatment at the same facility and "fragmented care" was designated when a patient received treatment at two or more facilities. Multivariable logistic regression was performed to identify factors associated with fragmented care. Overall survival was compared using Kaplan-Meier and Cox proportional hazards methods.
Results: A total of 536,896 patients met the study criteria, of which 317,038 (59.1%) patients received coordinated care and 219,848 (40.9%) patients received fragmented care. Decreased mortality was seen with fragmented care in stage II and III patients (hazard ratio (HR): 0.92 and 0.94 respectively; 95% confidence interval (CI): 0.88-0.97, 0.89-0.99; P < 0.001), and receipt of care at an Academic/Research Program (HR: 0.89; 95% CI: 0.84-0.93). Unexpectedly, living greater than 50 miles away from the treating facility was also associated with decreased mortality (HR: 0.85; 95% CI: 0.81-0.90]), although this represented a small minority of patients (N = 30,290, 6.5%).
Conclusions: For patients with early-stage breast cancer, receipt of fragmented care and greater distance to treating facility were not associated with worse outcomes. These results support patients' receipt of some care locally, underscoring the need for effective communication across the clinical care team.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2024.11.044 | DOI Listing |
Life Metab
February 2025
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
In Vitro Model
February 2022
Institute of Bioinformatics & Biotechnology, Savitribai Phule Pune University, Pune, India.
Purpose: The aggressive nature of a tumor is presumably its inherent one, but different environmental cues can manipulate it in many ways. In this context, the influence of metabolic stresses on tumor behavior needs to be analyzed to understand their far-reaching implications on tumor aggression and dormancy. This work investigates different facets of the tumor, such as tumorigenic capacity, tumor phenotype, and migration, under multiple metabolic stress conditions.
View Article and Find Full Text PDFIn Vitro Model
June 2024
School of Sport, Exercise and Health Sciences, Loughborough University, Towers Way, Loughborough, LE11 3TU UK.
[This corrects the article DOI: 10.1007/s44164-023-00055-y.].
View Article and Find Full Text PDFWorld J Gastrointest Surg
January 2025
Department of Gastrointestinal Surgery, The Second People's Hospital of Lianyungang, Lianyungang 222000, Jiangsu Province, China.
Background: According to statistics, the incidence of proximal gastric cancer has gradually increased in recent years, posing a serious threat to human health. Tubular gastroesophageal anastomosis and double-channel anastomosis are two relatively mature anti-reflux procedures. A comparison of these two surgical procedures, tubular gastroesophageal anastomosis and double-channel anastomosis, has rarely been reported.
View Article and Find Full Text PDFBio Protoc
January 2025
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Recurrent hormone receptor-positive (HR+) breast cancer is a leading cause of cancer mortality in women. Recurrence and resistance to targeted therapies have been difficult to study due to the long clinical course of the disease, the complex nature of resistance, and the lack of clinically relevant model systems. Existing models are limited to a few HR+ cell lines, organoid models, and patient-derived xenograft models, all lacking components of the human tumor microenvironment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!